07 Feb

Achieving Patient Adoption: Should Digital Health Tools Smile?

By Jim Joyce, CEO & Co-Founder of HealthBeacon and Dr. Zara Fullerton Kinsella, Medical Science Liaison for HealthBeacon

This is the second series reflecting on the adoption of healthcare technologies. In this piece, Jim Joyce asks the question – “Should Digital Health Tools Smile?”

“I gave them a smile, they gave me one back, so I gave them another”– Unknown

Should Digital Health tools smile at you?  I’m called into a packaging meeting for final sign off on the box that will deliver HealthBeacon Smart Devices to patients across the USA, in this case, it is for a partnership with one of the biggest healthcare providers in the USA. Our brilliant tech and design team have spent considerable time brainstorming the box and answering questions: Will a patient know what to do when they receive it? Is it easy to open? Easy to take the device out? Will it be intuitive to plug-in and set up? These are all critical questions that we believe we have a good handle on, but my team has one final point of debate. Should we put a smile on the inside flap of the box? For me, the answer is clear, but we paused for a moment to consider the smile. As a company, we operate globally across 20 countries and even within America the meaning of a smile may be interpreted differently across different states, context and demographics.

Our history with the question, “Should it smile?”, goes back to our earliest prototype, the way our technology works is that each time a patient uses the HealthBeacon device by disposing of their used injection into the HealthBeacon the device smiles at you through the LCD screen.

We initially included the smile because the first versions of our device needed up to 60 seconds to send the time-stamped image of your medication to our servers through a mobile network. During the transition time, many people thought the device might not be working so we introduced the smile during the transmission with the words “Well Done”. The feedback from our patients was great,  “I love how it smiles at me” and “I don’t want to disappoint my HealthBeacon, because I know it wants me to feel better”. The small smile on the screen introduced a bit of humanity to a fairly technical activity of injecting yourself subcutaneously and then disposing of your used injection into our device. Now our devices are communicating immediately, but we have kept the smile.

I was recently at a lecture hosted by the Euronext Stock Exchange, where Dermot Crowley, Deputy CEO of the hotel group, Dalata, paused for a moment to talk about the importance of guests being greeted by smiling staff at each of their hotels. He stated that the first thing he notices is whether the staff smile. It is a critical moment when a guest walks into our hotels, they may be tired from travel or disorientated and being welcomed with a smile can make all the difference.

So why the debate on whether to include a smile? What’s the counterpoint? You’re not taking something seriously and healthcare is serious. You’re not being authentic in your smile? Once a European pharmaceutical executive told me I was being “too American” and the smile might be considered condescending, “it won’t work here, we just don’t smile that much.”

I asked Dr. Zara, our Medical Science Liasion to comment on the science behind the smile:

“Smiling is something we are all familiar with; many of us smile more than 20 times a day and children often smile as much as 400 times in a 24 hour period 1 but what about the science behind these smiles? 

There has been a vast amount of research focusing on the smile, dating as far back as 1862, when French anatomist, Guillaume Duchenne described the results of his work stimulating facial muscles with electric currents and emphasised the significance of eye muscle contraction when smiling. Today, this Duchenne smile, is more commonly referred to as ‘Smizing’.3

The ability of facial expressions to impact our mood was first described by William James and Charles Darwin 4,5 and has been the subject of much research.6 Smiling has been associated with the release of neurotransmitters such as serotonin and dopamine with associated health benefits.

The long-term benefits of smiling are also fascinating.2 Smiling has been linked with increased lifespan in professional athletes 8 and higher levels of marital satisfaction and wellbeing.9 Furthermore, research by Hewlett Packard and Dr. Lewis found that a single smile can result in the same level of brain stimulation as consuming 2,000 bars of chocolate, or obtaining a significant amount of cash.10 

At HealthBeacon we believe we can back up the smiles, it’s part of the culture and it makes sense that we would embed our culture in our technology, communications and packaging.  We want our technology to remove pain, burden, isolation and reduce complexity. We understand that we are a small piece of a big puzzle to help our customers live happier and healthier lives. In a recent in-person survey at HealthBeacon, 90% of our staff spontaneously responded to a smile with a smile. Since smiling is clinically proven to be contagious we are hoping we will infect the last 10% of the staff.

Are we serious enough? The evidence suggests that smiling in the workplace has a direct correlation to productivity and competence, but it does have its limitation and there are times when the absence of a smile is an important message. In our new companion app, we are working on a module that will have people earn their smile, it’s early days so we don’t yet know the impact, but we will keep you posted.

So for the inside flap of the box, it’s a “Yes”. We believe the evidence is clear and it will bring a bit of humanity to the box. Sometimes it just makes sense to not overthink things and smile.

_________________

ABOUT

This article was written by Jim Joyce and Dr. Zara Fullerton Kinsella, HealthBeacon. Zara has a keen interest in digital health, particularly in the potential for disruptive technologies to enable individualised models of care, within the context of limited healthcare resources.

Jim Joyce has an MBA from University College of Dublin and BA in Economics from Fordham University. He is the CEO and Co-Founder of HealthBeacon, A Dublin Ireland based medical adherence technology company.

Jim Joyce, CEO of HealthBeacon

Dr. Zara Fullerton Kinsella has a degree in Business and Economics from Trinity College Dublin and a Medical Degree from University College Cork. She is the Medical Science Liaison at HealthBeacon.

Dr. Zara Fullerton Kinsella

MEDIA CONTACT

If you have any thoughts about this article, please get in touch at comms@healthbeacon.com or engage with HealthBeacon on LinkedIn or Twitter. We would love to hear from you!

 

[1] Goodman, R., 2011, The Untapped Power of Smiling, Forbes. https://www.forbes.com/sites/ericsavitz/2011/03/22/the-untapped-power-of-smiling/#1284fb7d7a67
[2] Jaffe, E., 2010, The Psychological Study of Smiling, https://www.psychologicalscience.org/observer/the-psychological-study-of-smiling
[3] Duchenne G.B., 1990, The mechanism of human facial expression, translation R.A. Cuthbertson, Cambridge University Press
[4] Darwin, C., 1872, The Expression of the Emotions in Man and Animals, London: J. Murray
[5] Goleman, D., 1989, A Feel Good Theory: A Smile Affects Mood https://www.nytimes.com/1989/07/18/science/a-feel-good-theory-a-smile-affects-mood.html
[6] Skibba, R., 2016, Psychologist argue about whether smiling makes cartoons funnier, Nature Journal of Science, https://www.nature.com/news/psychologists-argue-about-whether-smiling-makes-cartoons-funnier-1.20929
[7] Riggio, R., 2010, There’s Magic in Your Smile, https://www.psychologytoday.com/us/blog/cutting-edge-leadership/201206/there-s-magic-in-your-smile
[8] Abel E. and Kruger M.,2010, Smile Intensity in Photographs Predict Longevity, Psychological Science, 21, 542–544
[9] Harker L. and Keltner D. 2001, Expressions of Positive Emotion in Women’s College Yearbook Pictures and Their Relationship to Personality and Life Outcomes Across Adulthood. Journal of Personality and Social Psychology, 80, 112, 124
[10] Rickman, C., 2019, The Happiness Bible: The Definitive Guide to Sustainable Wellbeing
30 Jan

Adoption of Healthcare Technology: A Unique Dilemma

By Katie Roche and Dr. Zara Fullerton Kinsella, Medical Science Liaison for HealthBeacon | Illustrations by Luke Higashikawa

Companies feed our endless appetite for healthcare technologies, but are patients really using them? Read Katie Roche and Dr. Zara Fullerton Kinsella’s thoughts, the first of four articles reflecting on the adoption of healthcare technologies. In this piece, they explore why the rapid adoption of technology seen in other industries has lagged behind in healthcare, despite clear requirements for innovative solutions.

Introduction – Adoption of Healthcare Technology: A Unique Dilemma

At this time of the year, consumers are scrambling to obtain the latest technology. Companies feed this endless appetite for new technology by continuously promoting new versions of products year upon year. As the industry continues to capitalize on this frenzy and our lives become increasingly dependent on digital therapeutics, the extent of our choices increases exponentially. In 2008, there were 500 apps available on the Apple App Store.1 In 2018, consumers downloaded 194 billion apps and spent $101 billion in app stores.1 At the beginning of 2019, consumers had a choice of 2.2 million iOS apps and 2.6 million Android apps.1 The healthcare industry is no exception.

Technology and the Healthcare Industry

Recent years have seen an explosion in healthcare-related technologies; connected devices, wearable sensors, patches, apps and software. This sector is expected to reach $280 billion by 20212 and global healthcare spending is predicted to reach $10 trillion by 2022. 2 Patients and healthcare practitioners alike believe that technology has the potential to transform the way in which healthcare is delivered. Despite a rapid explosion in healthcare apps, developing technology for the healthcare industry involves countless additional barriers and considerations. Many healthcare providers are struggling in an under-resourced system and one would be forgiven for thinking that they would embrace every technology that promises to improve efficiency in the diagnosis and management of patients. However, there has been real resistance to processes that have been easily and rapidly adopted in other sectors. Why can’t these processes translate to healthcare?

What is Adoption?

Adoption can be described as the process of accepting, integrating and using a technology. Society has come to demand instant results and technology must continuously find innovative ways to ensure that participants remain engaged in a crowded marketplace after the initial excitement has passed. Many technologies struggle to provide the continuous utility that is required to ensure that initial uptake translates to long-term use. Technology needs to be easy to use, intuitive and aesthetic, solve a problem and in a manner that is decidedly better than a low-fi alternative solution.

Healthcare Technology Adoption Drivers and Barriers

How Can Digital Solutions Integrate into the Healthcare System?

New technologies must identify and address the needs of the end-user and all relevant stakeholders. For busy patients, carers, healthcare practitioners and insurers there must be some incentive in terms of increased quality of care, resource-saving or convenience. The technology must be financially accessible with a simple onboarding process and the ability to adapt to a wide and varied patient population. The device must be passive, require minimal use or capitalise on existing routines. Data generated by the technology must be easily understood and actionable to support patients in taking an active role in their health. As hospital systems move towards electronic health records, the data must be easily and effectively implemented into existing workflows to enable information sharing across all platforms on a real-time basis.

Data Protection in the Context of GDPR

Following the introduction of GDPR, there are significant financial penalties associated with mismanaged personal data. Patients need to trust the security of their data particularly when it relates to highly sensitive information. Data breaches can have a long term impact on the public’s trust, both at the level of an individual organisation but also in an entire industry as a whole. Companies who prioritize data security and integrity will gain consumer confidence as this becomes an increasing priority for many individuals.

Is Establishing a Credible Clinical Research Portfolio Worth it?

To survive in an industry full of highly qualified professionals and experts, healthcare technologies must withstand a continuous level of rigorous scientific and legal scrutiny. With such a significant volume of new devices arriving to market on a daily basis, it can be close to impossible to differentiate the truly beneficial technologies. Many companies have managed to present compelling and accurate clinical evidence and have reaped the financial rewards as demonstrated by some lucrative acquisitions and IPO valuations in recent years. Establishing a credible portfolio of clinical evidence presents a challenge for many emerging companies that may not have the financial resources required to clinically prove the value of their technologies.

High Risk and What Reward?

The disruptive innovation seen in the tech industries whereby a product is placed on the market almost prematurely is not acceptable when it comes to healthcare.  In a highly regulated, risk-averse, litigious industry such as healthcare, disruptive technologies may be met with a level of skepticism. Practitioners may be hesitant to recommend technologies that do not have a wide volume of clinical research and a well-structured data management platform.

How Can These Technologies Maintain Engagement?

After creating scientifically-backed, economically viable and legally compliant technology, there is still the issue of continued engagement of users. Many technologies are utilising gamification to maintain user interest over a prolonged period of time. Other devices use smartphone notifications such as text messages to engage users, but this also comes with the risk of notification fatigue and information overload. Increased interaction with technology may result in increased engagement, but for some patients, this may merely act as a reminder of their illness and have the opposite effect.

What Can We Learn About Long Term Adoption of Technology Within Healthcare?

As with other industries, following the enthusiasm, the hype and race to contribute to the growing body of tech, we anticipate the decline; the redundancy and oversupply, notification fatigue, user boredom and finally, abandonment.  This is a conversation that must be had. How do we create and refine tech that is actually helpful, engages patients long term, reduces healthcare costs, and results in improved patient outcomes? Can we learn from other industries and apply these insights to this space?

…………………………………………………………………………………………………….

About:

This article was written By Katie Roche and Dr. Zara Fullerton Kinsella, HealthBeacon. Katie and Zara have a keen interest in digital health, particularly in the potential for disruptive technologies to enable individualised models of care, within the context of limited healthcare resources.

Katie Roche has a degree in Neuroscience and has recently started a degree in Medicine at the University of Melbourne, Australia. Katie recently completed a medical internship at HealthBeacon’s Dubin office.

Katie Roche

Dr. Zara Fullerton Kinsella has a degree in Business and Economics from Trinity College Dublin and a Medical Degree from University College Cork. She is the Medical Science Liaison at HealthBeacon.

Dr. Zara Fullerton Kinsella

Media Contact:

If you have any thoughts about this article, please get in touch at comms@healthbeacon.com or engage with HealthBeacon on LinkedIn or Twitter. We would love to hear from you!

References

  1. The State of Mobile in 2019, App Annie. Available at https://www.appannie.com/en/go/state-of-mobile-2019/
  2. Deloitte 2019 Global HealthCare Outlook, Shaping the Future. Available at https://www2.deloitte.com/content/dam/Deloitte/global/Images/infographics/lifesciences-healthcare/gx-lshc-hc-outlook-2019-infographic.pdf
10 Jan

HealthBeacon to present on their US expansion during the 37th Annual J.P. Morgan Healthcare Conference

HEALTHBEACON TO PRESENT ON THEIR U.S. EXPANSION FOR THEIR FDA CLEARED ADHERENCE TECH FOR INJECTABLE MEDICATION DURING THE  37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

[Boston, MA., Jan. 10 2020] – HealthBeacon, a medication adherence technology company that develops smart tools for managing medication, today announced that Jim Joyce, CEO and Co-Founder, will present at the Digital Medicine & Medtech Showcase™ in San Francisco on Tuesday, January 14th at 11:00 am Pacific time.

Jim Joyce, CEO will be announcing HealthBeacon’s US expansion for their FDA cleared adherence technology for injectable medication at Digital Medicine & Medtech Showcase as follows:

Date: Tuesday, January 14, 2020

Time: 11AM (PST)

Room: Balboa (Level 4)

Venue: Parc 55 – A Hilton Hotel, 55 Cyril Magnin Street, San Francisco, CA (United States)

 

Jim Joyce, CEO & Co-Founder

ABOUT HEALTHBEACON

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication at home. HealthBeacon’s FDA cleared smart sharps bin tracks patient injection history, provides personalized interactive reminders and safely stores used injectables. With the intervention of HealthBeacon’s Smart Sharps Technology, patients’ persistence and adherence increased by 25-30% within twelve months of initiating therapy.  The HealthBeacon integrated model connects a patient’s routine and the prescribing clinician’s workflow.  This technology has been adopted across thirteen countries with >300,000 injections tracked since launch in 2014, with a patient acceptance rate of 80-90%. For more information, visit: www.healthbeacon.com or engage with HealthBeacon on LinkedIn or Twitter.

Media Contact:

Mary Principe | comms@healthbeacon.com

05 Dec

BIBA Delegates Visit HealthBeacon in Dublin

HealthBeacon, a Dublin and Boston based medication adherence technology company that develops Smart Tools for Managing Medication welcomed the Boston Irish Business Association (BIBA) and its 2019 trade mission delegation to it’s Dublin headquarters on Monday, December 2nd.

BIBA Delegates at HealthBeacon HQ

HealthBeacon Co-Founders: Kieran Daly & Jim Joyce

 

 

 

 

 

 

 

 

The purpose of the trade mission is to look at the potential for transatlantic collaboration in order to strengthen links between businesses in Ireland and Boston. The trade mission was led by Laura Hamilton, who is the newly appointed CEO of HealthBeacon’s North American operations.

As President of the Boston Irish Business Association, it was my distinct pleasure to lead an impressive delegation on a Trade Mission across the island of Ireland visiting Belfast, Derry, Donegal, Dublin, Kildare and Cork. A highlight was visiting HealthBeacon HQ in Dublin. It’s been an incredible few weeks since joining the team as their new CEO of North America.” says Hamilton.

HealthBeacon members welcomed the Boston Irish Business Association (BIBA) and its 2019 trade mission delegation BIBA to their facility. HealthBeacon’s CEO, Jim Joyce guided delegates around the HQ touring the Data labs which has a dedicated Data Analyst team serving up valuable actionable insights and analysis, the production lab where the HealthBeacon units are assembled and configured and it’s enthusiastic customer service team which supports the HB offering to patients.

Having the BIBA delegation visit HealthBeacon in Dublin truly showcases the value of growing international business relationships, sustaining the effort, and then capitalizing on opportunities as a result of the endeavor.” Says Hamilton.

HealthBeacon’s technology has been adopted across 13 countries with over 300,000 injections tracked since its launch in 2014 and a patient acceptance rate of 80-90%. For patients that are treated on chronic injectable therapy for conditions that range from Multiple Sclerosis, Crohns Disease, Rheumatoid Arthritis, Asthma, to Severe Migraines many of them fail on therapy due to non-adherence. The data is clear that without support between 40-50% of patients will fail on therapy in the first year.

HealthBeacon’s Smart Sharps Technology has demonstrated a 25-30% increase within twelve months of initiating therapy.  The key to their success is the powerful simplicity of their technology and how it easily integrates into the patient’s routine and the prescribing clinician’s workflow.

HealthBeacon and BIBA Delegates

CEO Jim Joyce welcoming BIBA

CTO, Kieran Daly with Delegates

 

 

 

 

Sr Manager – Contracts & Reimbursements, Alan Dalton

HealthBeacon Smart Sharps Bin

3D Printer

 

04 Dec

HealthBeacon welcomes Boston Irish Business Association to its Dublin HQ

Silicon Republic: Kelly Earley is a journalist with Siliconrepublic.com

HealthBeacon’s new CEO for North America, Laura Hamilton, hopes to strengthen links between businesses in Ireland and Boston.

This week, medtech firm HealthBeacon, which is headquartered between Dublin and Boston, welcomed the Boston Irish Business Association (BIBA) and its 2019 trade mission delegation to the company’s Irish headquarters.

The trade mission was led by Cork-born Laura Hamilton, who is the newly appointed CEO for HealthBeacon’s North American operations. As well as leading the company’s US arm, Hamilton is also the current BIBA president.

The Boston delegation’s visit to HealthBeacon was one stop on a journey through Belfast, Donegal, Derry, Dublin and Cork. The purpose of the trade mission is to look at the potential for transatlantic collaboration. It is hoped that the mission will bring together high-profile US business leaders to grow and strengthen business relationships throughout Ireland.

The BIBA delegates were given a site tour and product overview of HealthBeacon’s Dublin facility, which was led by the company’s co-founder Jim Joyce, who is also a Boston native.

HealthBeacon is developing smart tools for managing medication. Its Smart Sharp Bin aims to make it easier for patients using injectable medicines to stay on track with their treatment schedule and allow carers to track a patient’s progress.

Poised for US growth

Hamilton, who was born in Cork but grew up in Boston, played an instrumental role in bringing BIBA to Ireland for the first time in 10 years.

“After years of planning and discussion, I am thrilled to lead the BIBA trade mission to Ireland, especially as the incoming HealthBeacon CEO for the North American division,” Hamilton said.

“I have been closely connected to HealthBeacon for many years and admire the leadership, the team they’ve developed and early success achieved across Europe.

“The business is poised for tremendous growth in North America through creating value in the healthcare ecosystem with a unique world leading technology, tracking patient adherence with injectable medications for chronic disease.”

To date, HealthBeacon’s platform has been used to track more than 300,000 injections in patient’s homes. The Smart Sharp Bin has been launched in 13 countries.

Joyce said: “I first got to know Laura over four years ago in her time as director of business development at the Massachusetts Biotechnology Council (MassBio) and as BIBA president. HealthBeacon are delighted to appoint a talented business innovator and welcome this important trade mission to our Irish headquarters.”

Since it was founded in 2013, HealthBeacon has raised $15m in funding. Earlier this year, the company announced plans to expand into Asia and the US.

HealthBeacon welcomes Boston Irish Business Association to its Dublin HQ

21 Nov

Laura Hamilton to become CEO of North America for HealthBeacon

Laura Hamilton to become CEO of North America for HealthBeacon

Nov 21ST 2019, Dublin, Ireland and Boston Headquartered, HealthBeacon, a leading global medical adherence technology provider whose mission is to “build smart tools for managing medications” will be establishing a dedicated North American division to drive the development of its business and technology platform across the USA and Canada.

It’s FDA cleared “best in class” medical adherence tool for tracking injectable medications has already been launched in 13 countries and has tracked over 300,000 Injections in patient’s homes, globally. At the recent Connected Health Conference in Boston, HealthBeacon published peer-reviewed evidence demonstrating the ability for patients to successfully adopt their technology as a result of patient-centered design.  The platform has been designed to improve long term adherence to medication regimes and provide critical health data back to clinicians.

HealthBeacon’s Boston office can be described as just “Off Broadway” located above the CVS pharmacy on West Broadway in South Boston. Their Boston office has full business development, technical operations and customer care capabilities which are integrated into clinical systems, research organisations, and pharmaceutical patient support programs.

In her role as CEO of North America, Laura will be responsible for developing both the market and the HealthBeacon organisation across this important region and will report into Co-Founder and CEO, Jim Joyce.

I first got to know Laura over 4 years ago in her time as Director of Business Development of the Massachusetts Biotechnology Council (MassBio) and in her capacity as President of BIBA (Boston Irish Business Association). She is a high energy, talented leader and we couldn’t be more excited to welcome her into the company at such an exciting time.Jim Joyce, CEO and Co-Founder, HealthBeacon.

Upon joining the company this week, Laura stated, “I am delighted to be joining HealthBeacon as CEO of North America, based at the US Headquarters in Boston, MA. I’ve been closely connected to the company for many years and truly admire the leadership, the team they’ve developed, as well as the early successes they’ve achieved across Europe. The business is poised for tremendous growth in North America and is creating value in the healthcare ecosystem with their world leading technology, which tracks patient adherence to injectable medications for chronic disease. I’m so looking forward to getting started and joining the team of one of Ireland’s most innovative start-ups.

MassBio President & CEO Robert Coughlin added, “The convergence between digital health and the life sciences is creating incredible opportunities to transform patient care. With Laura joining the team, I am excited to watch HealthBeacon grow in Massachusetts and beyond as it advances solutions to improve health outcomes.

Laura most recently served as Executive Vice President, US Operations for RxCelerate, an outsourced drug discovery and drug development platform company based in Cambridge UK. Prior to that role, Laura was Director of Business Development at MassBio. She is a proud three-time graduate of Northeastern University in Boston with a BSBA in Finance, Masters Degree in Innovation (MSc) and Master of Business Administration (MBA). A native of Cork, Ireland, Laura is currently the President of the Boston Irish Business Association (BIBA) and also serves on the Board of Directors at the American Heart Association – Metro Boston.

Laura Hamilton HealthBeacon’s CEO of North America

HealthBeacon Boston Office

13 Nov

The Impact of Connected Devices on Medication Adherence

Sean Glynn, M.S., is the Director of HEOR and Strategic Initiatives for HealthBeacon in North America

Zara Fullerton Kinsella, Medical Doctor, is the Medical Science Liaison for HealthBeacon

A physician recently described an interaction where a patient was ending a course of therapy due to a poor response to treatment. The patient asked, “What should I do with the leftover medication I have at home?”  The doctor replied, “I thought you said you were taking all of your medication.  Why do you have leftover medication?”

This is not an isolated event. One out of every two patients fail to take their medication as directed and have stopped treatment within a twelve-month period. For those of us familiar with the medication non-adherence problem, this is not surprising. Hippocrates was known to have said, “Keep a watch also on the faults of the patients, which often make them lie about the taking of things prescribed.”

Our generation is asking for connected devices to be a positive force for change in every aspect of health support, and adherence is no exception. The health and technology industries are making multi-billion dollar investments so that connected devices can fundamentally transform the delivery of healthcare. Technology offers a wide variety of solutions from smart packaging to robotic dispensers, the Internet of Things offers connected devices that monitor when medicine is unpackaged and even when a used needle is disposed into a smart sharps container. Mobile technology can remind and reward patients to help them stay on track with their medication and software platforms convey, synthesize and prioritize cohort data for clinicians. In addition, artificial intelligence can offer insights into big data and predict required interventions before a patient becomes symptomatic.

Getting health data from patients has challenged the industry to innovate. Our approach at HealthBeacon has been to use the Internet of Things to passively track what the patient is already doing, in this case, disposing of a used pen or syringe into a sharps container. By capturing this behavior and relaying the information to patients, caregivers and physicians, a key data point is created. This collection of data on a real-time basis can serve to increase patient engagement, lead to more informed clinical decision making and ultimately enable the early identification of patients who may benefit from interventions that focus on improving adherence.

If this patient had been in possession of an adherence monitoring device, their story would have been very different. Any missed doses of medication would have immediately been identified and shared with their healthcare provider or caregiver, enabling them to receive the support they need to maximize outcomes from their treatment.

Connected devices have the potential to identify and support those patients who need the most help with managing their medication. Given the magnitude of this group, these technologies have a transformative role to play in improving patient care and enriching the relationship between physicians, patients and caregivers.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

13 Nov

HealthBeacon appoints Sean Glynn as first Director of HEOR, and Dr. Zara Fullerton Kinsella as first Medical Science Liaison

HealthBeacon appoints first Director of HEOR and hires first Medical Science Liaison.

(Dublin, Ireland; Boston, MA, – November 13th, 2019) Leading medication adherence technology company, HealthBeacon has announced the appointments of Sean Glynn as Director of Health Economics and Outcomes Research, and Dr. Zara Fullerton Kinsella as Medical Science Liaison.

Sean Glynn, Director of HEOR, joined the HealthBeacon team three years ago with the critical role of launching HealthBeacon’s operations in the US. Sean’s background in behavioral sciences and his deep understanding of the medication adherence issue will be instrumental in furthering HealthBeacon’s mission to improve patient outcomes by delivering new adherence solutions to patient’s who self-administer injectable medications in their homes. Sean is based out of HealthBeacon’s Boston office.

Dr. Zara Fullerton Kinsella has joined the HealthBeacon team as a Medical Science Liaison, to facilitate clinical research and assist with Regulatory Affairs. Zara is a medical doctor with an undergraduate degree in Business and Economics at Trinity College. Her keen interest in healthcare led her to study Graduate Entry Medicine at University College Cork. As a junior doctor, she worked in a variety of medical specialties. Zara is based out of HealthBeacon’s office in Dublin, Ireland.

These appointments will further HealthBeacon’s commitment to evidence-based decision making and program design. “We are excited to expand our team and add these critical capabilities with Sean being promoted to Director of HEOR and Dr. Zara joining the team as our Medical Science Liaison” said Jim Joyce, CEO of HealthBeacon, “these roles will bring through our latest studies, data projects and provide important medical insights into product development.”

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication at home. HealthBeacon’s FDA cleared smart sharps bin tracks patient injection history, provides personalized interactive reminders and safely stores used injectables. With the intervention of HealthBeacon’s Smart Sharps Technology, patients’ persistence and adherence increased by 25-30% within twelve months of initiating therapy. The HealthBeacon integrated model connects a patient’s routine and the prescribing clinician’s workflow. This technology has been adopted across thirteen countries with >300,000 injections tracked since launch in 2014, with a patient acceptance rate of
80-90%.

 

HealthBeacon’s Medical Science Liaison Dr. Zara Fullerton Kinsella

HealthBeacon’s HEOR Sean Glynn

Media Enquiries: Mary Principe  | Email: events@healthbeacon.com

18 Sep

HealthBeacon reveals strategic investors in Asia and the US, SGInnovate and Manatt Health

HealthBeacon, a medication adherence technology company based in Dublin receives investment from international strategic partners, SGInnovate and Manatt. 

(Dublin, Ireland; Singapore, – September 18th, 2019) Dublin and Boston based digital health company, HealthBeacon announces that SGInnovate (Singapore) and Manatt (USA) have become strategic investors in HealthBeacon as part of the final completion of the Series A fundraising announced in January. The total Series A fundraising was $12M bringing the total funding into the company of $15M.

Jim Joyce, Co-Founder, and CEO of HealthBeacon said, “We are delighted to have SGInnovate and Manatt on board as investors and strategic partners will assist us significantly as we bring our medical adherence technology to patients in the Asian and USA markets.”

HealthBeacon continues its expansion plan into the Asian Market. Hsien-Hui Tong, SGInnovate’s Head of Venture Investing said, “Medical non-adherence places a significant burden on healthcare systems. HealthBeacon’s use of Smart Tools to tackle this global challenge resonates well with SGInnovate’s belief in investing in best-in-class Deep Tech tackling difficult problems faced around the world. The team has shown a proven track record in improving care for patients with chronic medical conditions in Europe, the US, and Canada. SGInnovate is proud to join in as a strategic investor to help with the company’s expansion into Asia. This also marks our first healthcare investment together with Enterprise Ireland. We look forward to supporting more promising Deep Tech startups globally.”

Hsien-Hui Tong of SGInnovate. Image: SGInnovate

Lisa Suennen, Leader of Manatt said, “HealthBeacon has a proven team that is tackling a challenging and unaddressed problem in a new way. Their solution is one that both helps patients directly and improves caregivers ability to help them manage difficult conditions. We are excited to support the company and watch it grow.”

Manatt leader Lisa Suennen. Image: Manatt

The addressable market for injectable medications has reached nearly $50 billion. As of today, HealthBeacon operates in 13 markets and has tracked more than 300,000 home-based injections making it one of the largest global deployments of a medical adherence device. Today HealthBeacon employs over 40 people and plans to continue its growth over the next 18 months.

The smart sharps bin system by HealthBeacon has made it easier for patients, using injectable medications, to stay on track with their treatment schedule. This has resulted in improved patient medication adherence and driving patient care.

About SGInnovate:

SGInnovate is a private limited company wholly owned by the Singapore Government. With the support of our partners and co-investors, we back deeply technical founders through equity-based investments, access to talent, and support in building customer traction. Our efforts are prioritised around transformational technologies such as Artificial Intelligence, Quantum Tech, and MedTech, which represent impactful and scalable answers to global challenges.

About Manatt:

Manatt is an integrated professional services firm that provides strategic consulting and legal support to large and small companies.  Manatt has transformed from one of the top law firms to an industry-leading, integrated professional services firm that combines its legal capabilities with deep strategic, analytics and public policy capabilities through Manatt Health and its digital and technology businesses. Manatt Health’s interdisciplinary teams are known for engaging in leading-edge thought leadership, often working with the major healthcare foundations to develop new thinking on complex healthcare issues.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

22 Jul

U.S. Growth Hormone Adherence Patient Survey Results

Study finds that patients on growth hormone medications have difficulty adhering to their medication schedule

HealthBeacon and The MAGIC Foundation announce discoveries from a patient survey

(Boston,MA; July 16th, 2019) HealthBeacon, a medication adherence technology company, and The MAGIC Foundation, the world’s leading advocacy and information group for human growth disorders, have carried out a survey which highlights the adherence issues for patients on growth hormone medication.

Poor adherence to treatment of chronic diseases is a worldwide problem and adherence to long-term therapy for chronic illnesses in developed countries is averaging 50%. The survey highlighted a trend towards poor adherence over duration of treatment with an important drop after the first year. Across all demographics surveyed, the top reason for the patient missing their medication was due to “being too busy and forgetting”.

HealthBeacon’s Director of Operations for North America, Sean Glynn said, “It was interesting to note that one-in-five patients are self-reporting suboptimal adherence levels, highlighting the need for smart tools and support to help stay on track with treatment.” Smart Tools such as the HealthBeacon smart sharps bin system has made it easier for patients, using injectable medications, to maintain their treatment schedule and this has resulted in improved persistence to treatment by 20-30% within the first year.

“This is an important look into the challenges associated with long-term treatment for chronic conditions such as growth disorders,” commented Dianne Kremidas, Executive Director at The MAGIC Foundation. “We are delighted to share these results with patients, physicians and pharmaceutical companies to bring light to this critical issue.”

The MAGIC Foundation is the global leader in endocrine health, advocacy, education, and support. HealthBeacon believes that engaging with the world’s leading advocacy groups will provide a strong network and patient engagement program to improve medication adherence.

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule and uses customized reminders to help them start and stay on track with medication. The technology has been on the market since 2013 and has tracked > 270,000 injections and is now available in the US Market. To learn more, email events@healthbeacon.com.

About The MAGIC Foundation

The MAGIC Foundation was incorporated in the state of Illinois and received 501(C)3 non-profit status October 29, 1989. Since its inception, the Foundation has grown to include support services for adults who were also impacted by these disorders.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

© 2015 Health Beacon - Privacy Policy - Website by Medusa